title: Antibody Responses After Analytic Treatment Interruption in Human Immunodeficiency Virus-1-Infected Individuals on Early Initiated Antiretroviral Therapy.
abstract: The examination of antibody responses in human immunodeficiency virus (HIV)-1-infected individuals in the setting of antiretroviral treatment (ART) interruption can provide insight into the evolution of antibody responses during viral rebound. In this study, we assessed antibody responses in 20 subjects in AIDS Clinical Trials Group A5187, wherein subjects were treated with antiretroviral therapy during acute/early HIV-1 infection, underwent analytic treatment interruption, and subsequently demonstrated viral rebound. Our data suggest that early initiation of ART arrests the maturation of HIV-1-specific antibody responses, preventing epitope diversification of antibody binding and the development of functional neutralizing capacity. Antibody responses do not appear permanently blunted, however, because viral rebound triggered the resumption of antibody maturation in our study. We also found that antibody responses measured by these assays did not predict imminent viral rebound. These data have important implications for the HIV-1 vaccine and eradication fields.
authors.affiliation: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School; Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts.
authors.forename: Kathryn E
authors.initials: KE
authors.lastname: Stephenson
authors.affiliation: Center for Virology and Vaccine Research , Beth Israel Deaconess Medical Center, Harvard Medical School.
authors.forename: George H
authors.initials: GH
authors.lastname: Neubauer
authors.affiliation: Center for Virology and Vaccine Research , Beth Israel Deaconess Medical Center, Harvard Medical School.
authors.forename: Christine A
authors.initials: CA
authors.lastname: Bricault
authors.affiliation: Center for Virology and Vaccine Research , Beth Israel Deaconess Medical Center, Harvard Medical School.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Shields
authors.affiliation: Center for Virology and Vaccine Research , Beth Israel Deaconess Medical Center, Harvard Medical School.
authors.forename: Madeleine
authors.initials: M
authors.lastname: Bayne
authors.affiliation: JPT Peptide Technologies , Berlin , Germany.
authors.forename: Ulf
authors.initials: U
authors.lastname: Reimer
authors.affiliation: JPT Peptide Technologies , Berlin , Germany.
authors.forename: Nikolaus
authors.initials: N
authors.lastname: Pawlowski
authors.affiliation: JPT Peptide Technologies , Berlin , Germany.
authors.forename: Tobias
authors.initials: T
authors.lastname: Knaute
authors.affiliation: JPT Peptide Technologies , Berlin , Germany.
authors.forename: Johannes
authors.initials: J
authors.lastname: Zerweck
authors.affiliation: Center for Virology and Vaccine Research , Beth Israel Deaconess Medical Center, Harvard Medical School.
authors.forename: Michael S
authors.initials: MS
authors.lastname: Seaman
authors.affiliation: Massachusetts General Hospital , Boston.
authors.forename: Eric S
authors.initials: ES
authors.lastname: Rosenberg
authors.affiliation: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School; Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts.
authors.forename: Dan H
authors.initials: DH
authors.lastname: Barouch
keywords: HIV eradication; HIV vaccine; antibody; microarray; treatment interruption